Castle Biosciences, Inc. Q3 2025 Earnings Recap

Castle Biosciences reported a pivotal quarter highlighted by the launch of AdvanceAD-Tx, a first-in-class gene expression test aimed at improving treatment outcomes for patients with moderate to severe atopic dermatitis.

Key Takeaways

• Successfully launched AdvanceAD-Tx, targeting a $33 billion market opportunity in the U.S. for moderate to severe atopic dermatitis.
• Clinical validation shows AdvanceAD-Tx can significantly improve treatment response rates for patients on JAK inhibitors versus traditional therapies.
• Approximately 80% of surveyed clinicians indicated intent to use AdvanceAD-Tx, underscoring strong market receptivity.
• The company plans to explore multiple reimbursement pathways to facilitate patient access and drive early adoption of the test.